The potential link between NKX3-2 and drug resistance is supported by research indicating that NKX3-2 is an EMT-related gene that may contribute to acquiring paclitaxel resistance in pancreatic carcinoma cells [31], suggesting its impact on chemotherapy response. Here, NKX3-2 is linked to exocrine pancreatic carcinoma.